Olivier Soula holds a PhD in Polymer Physico-Chemistry and an MBA. During the 8 years spent at Flamel Technologies, where he was Director of Research, he successfully led the development of Medusa, a sustained release platform for therapeutic proteins which was partnered with Bristol Myers Squibb (BMS).

In 2005, Olivier founded Adocia with his father, Gérard Soula, and his brother, Rémi Soula. Olivier has held successively the position of Director of Research and Development, Deputy Chief Executive Officer and then, Chief Executive Officer since 2023. He was instrumental in the signing of 4 major partnerships which represented more than 150 million dollars of revenue with Eli Lilly and with Tonghua Dongbao.

Olivier is co-author of more than 40 patents on protein delivery and has worked for more than 20 years in the field of innovative insulin formulations.

Mathieu-William Gilbert began his career with KPMG and Sanofi Aventis, in internal control and auditing, before joining Novo Nordisk’s finance functions and being appointed CFO of Algeria and then of the Latin American region.

Afterward, he held the position of Vice President & General Manager for six Latin American countries, overseeing all Novo Nordisk activities in the region. His responsibilities included establishing the Obesity franchise and the commercial launch of Ozempic®.

Finally, Mathieu served as Vice-President Strategic Projects of International Commercial Operations at Novo Nordisk, based in Zurich.